SCHEMBL2867149

SCHEMBL2867149

COc1ccc(Cn2c(=O)c(C#N)c(Cl)c3cc(OC)c(OC(C)C)cc32)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
RXFP1 Q9HBX9 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.41
THRB P10828 1/20 0.41
PDE1A P54750 1/20 0.41
PDE1B Q01064 1/20 0.41
PDE1C Q14123 1/20 0.41
MAPT P10636 5/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
GAA P10253 2/20 0.41
MAPK1 P28482 2/20 0.41
LMNA P02545 2/20 0.40
TSHR P16473 2/20 0.40
HTT P42858 1/20 0.40
P2RX4 Q99571 1/20 0.40
P2RX3 P56373 2/20 0.40
ALDH1A1 P00352 3/20 0.39
GRM2 Q14416 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2857645 0.94 KDM4E (0.52) KDM4ERXFP1PDE1APDE1BPDE1C
SCHEMBL2868419 0.88 PDE1A (0.42) KDM4EPDE1APDE1BPDE1CMAPT
SCHEMBL13025172 0.83 KDM4E (0.46) KDM4ERXFP1SMN1; SMN2THRBPDE1A
SCHEMBL2863880 0.78 P2RX4 (0.62) KDM4ESMN1; SMN2PDE1CMAPTMEN1
SCHEMBL2861684 0.78 SMN1; SMN2 (0.53) KDM4ERXFP1SMN1; SMN2THRBPDE1A
SCHEMBL2859347 0.78 KDM4E (0.43) KDM4ERXFP1MAPTMEN1KMT2A
SCHEMBL2865248 0.76 HTT (0.52) MEN1KMT2ALMNAHTTALDH1A1
SCHEMBL13025171 0.75 KDM4E (0.51) KDM4ERXFP1PDE1APDE1BPDE1C
SCHEMBL14195213 0.74 GABRA5 (0.49) KDM4EPDE1APDE1BPDE1CMAPT
SCHEMBL14195200 0.74 GABRA5 (0.47) KDM4EPDE1APDE1BPDE1CMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 KDM4E 1057/4885RXFP1 1309/4885SMN1; SMN2 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.